Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for Karyopharm Therapeutics (KPTI) over the last 9 years, with Q4 2020 value amounting to $297000.0.

  • Karyopharm Therapeutics' Current Deferred Revenue fell 9344.8% to $297000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $297000.0, marking a year-over-year decrease of 9344.8%. This contributed to the annual value of $297000.0 for FY2020, which is 9344.8% down from last year.
  • Per Karyopharm Therapeutics' latest filing, its Current Deferred Revenue stood at $297000.0 for Q4 2020, which was down 9344.8% from $297000.0 recorded in Q3 2020.
  • Karyopharm Therapeutics' 5-year Current Deferred Revenue high stood at $21.9 million for Q4 2017, and its period low was $263000.0 during Q1 2016.
  • Over the past 5 years, Karyopharm Therapeutics' median Current Deferred Revenue value was $1.1 million (recorded in 2017), while the average stood at $4.8 million.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Current Deferred Revenue soared by 772892.86% in 2017, and later crashed by 9344.8% in 2020.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Current Deferred Revenue stood at $280000.0 in 2016, then skyrocketed by 7728.93% to $21.9 million in 2017, then tumbled by 57.29% to $9.4 million in 2018, then crashed by 51.58% to $4.5 million in 2019, then crashed by 93.45% to $297000.0 in 2020.
  • Its Current Deferred Revenue stands at $297000.0 for Q4 2020, versus $297000.0 for Q3 2020 and $297000.0 for Q2 2020.